Related Experiment Video

Updated: Jun 5, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)]

A B Cortot1

  • 1Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44, Binney Street, D820, Boston, MA 02115, États-Unis. alexis cortot@dfci.harvard.edu

Revue De Pneumologie Clinique
|December 21, 2010
PubMed

Insights

Molecular targeted agents, including Epidermal Growth Factor Receptor (EGFR) inhibitors, are revolutionizing non-small cell lung cancer treatment. These therapies targeting EGFR are crucial for future lung cancer care.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecular targeted agents are transforming cancer therapy.
  • Epidermal Growth Factor Receptor (EGFR) inhibitors are key in treating non-small cell lung cancer (NSCLC).
  • EGFR's role in lung carcinogenesis is significant.

Purpose of the Study:

  • To detail the role of EGFR in lung carcinogenesis.
  • To outline therapeutic approaches for inhibiting EGFR activity.
  • To discuss clinical trial results of EGFR inhibitors.

Main Methods:

  • Review of scientific literature on EGFR.
  • Analysis of therapeutic strategies targeting EGFR.
  • Summary of major clinical trial outcomes for EGFR inhibitors.

Main Results:

  • EGFR inhibitors (tyrosine kinase inhibitors like gefitinib/erlotinib and monoclonal antibodies like cetuximab) are effective.
  • These targeted agents represent a major breakthrough in NSCLC treatment.
  • The clinical significance of EGFR inhibitors is projected to grow.

Conclusions:

  • EGFR inhibitors are vital in managing non-small cell lung cancer.
  • Targeting EGFR is a critical strategy in lung cancer therapy.
  • Further clinical evaluation and application of these agents are expected.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...